EGFR and head and neck squamous cell carcinoma: Cetuximab, a chimeric IgG1 monoclonal antibody against EGFR, was first approved by the U.S. Food and Drug Administration (FDA) in 2004 for patients with irinotecan-resistant colorectal cancer [26], and two years later was authorized for the treatment of locally advanced HNSCC [27].